^
    Apply
    Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) (NCT04020575)
    Phase 1
    Minerva Biotechnologies Corporation
    Recruiting
    Last update posted :
    06/16/2023
    Initiation :
    01/15/2020
    Primary completion :
    01/01/2025
    Completion :
    01/15/2035
    HER-2 • PGR • MUC1
    |
    HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative
    |
    huMNC2-CAR22 • huMNC2-CAR44 CAR T cells
    PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer (NCT05812326)
    Phase 1/2
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Completed
    Last update posted :
    04/13/2023
    Initiation :
    05/17/2019
    Primary completion :
    11/16/2022
    Completion :
    11/16/2022
    PD-1
    |
    MUC1 expression
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (NCT03198052)
    Phase 1
    Second Affiliated Hospital of Guangzhou Medical...
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    07/01/2017
    Primary completion :
    08/01/2024
    Completion :
    08/01/2026
    EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA
    |
    MSLN expression • EGFR positive • GPC3 expression
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    Multi-CAR T Cell Therapy for Acute Myeloid Leukemia (NCT03222674)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Unknown status
    Last update posted :
    10/17/2018
    Initiation :
    07/15/2017
    Primary completion :
    12/31/2019
    Completion :
    12/31/2020
    CD38 • CD33 • NCAM1 • IL3RA
    |
    Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
    CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer (NCT03706326)
    Phase 1/2
    The First Affiliated Hospital of Guangdong Phar...
    Unknown status
    Last update posted :
    10/16/2018
    Initiation :
    09/28/2018
    Primary completion :
    09/28/2021
    Completion :
    09/28/2021
    PD-1
    |
    MUC1 expression
    |
    anti-MUC1 CAR-T cells
    Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC (NCT03525782)
    Phase 1/2
    The First Affiliated Hospital of Guangdong Phar...
    Unknown status
    Last update posted :
    05/16/2018
    Initiation :
    02/01/2018
    Primary completion :
    01/31/2021
    Completion :
    01/31/2022
    PD-1
    |
    MUC1 expression
    |
    Keytruda (pembrolizumab) • anti-MUC1 CAR-T cells
    CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor (NCT03179007)
    Phase 1/2
    Shanghai Cell Therapy Research Institute
    Unknown status
    Last update posted :
    06/07/2017
    Initiation :
    06/07/2017
    Primary completion :
    01/20/2019
    Completion :
    04/20/2019
    MUC1 • CTLA4
    |
    MUC1 expression
    |
    cyclophosphamide
    Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor (NCT02587689)
    Phase 1/2
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Unknown status
    Last update posted :
    12/05/2016
    Initiation :
    10/01/2015
    Primary completion :
    10/01/2017
    Completion :
    10/01/2018
    HER-2 • ER • ALK • PGR
    |
    EGFR mutation • HER-2 negative • ER negative • ALK translocation • MUC1 expression
    |
    anti-MUC1 CAR-T cells